References of "Annals of the Rheumatic Diseases"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
Kirwan, J. R.; Hallgren, R.; Mielants, H. et al

in Annals of the Rheumatic Diseases (2004), 63(6), 688-695

Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with conventional glucocorticoid treatment and placebo in rheumatoid arthritis. Methods: A double blind ... [more ▼]

Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with conventional glucocorticoid treatment and placebo in rheumatoid arthritis. Methods: A double blind, randomised, controlled trial over 12 weeks in 143 patients with active rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7.5 mg daily, and placebo. Particular attention was paid to the pattern of clinical response and to changes in the four week period following discontinuation of treatment. Results: There were improvements in tender joint count and swollen joint count on budesonide 9 mg compared with placebo (28% for tender and 34% for swollen joint counts, p< 0.05). Prednisolone 7.5 mg gave similar results, while budesonide 3 mg was less effective. ACR20 response criteria were met by 25% of patients on placebo, 22% on budesonide 3 mg, 42% on budesonide 9 mg, and 56% on prednisolone 7.5 mg. A rapid and significant reduction in symptoms and signs in response to budesonide 9 mg and prednisolone 7.5 mg was evident by two weeks and maximal at eight weeks. There was no evidence that budesonide provided a different pattern of symptom control from prednisolone, or that symptoms became worse than placebo treatment levels after discontinuation of glucocorticoid treatment. Adverse effects attributable to glucocorticoids were equally common in all groups. Conclusions: The symptomatic benefits of budesonide 9 mg and prednisolone 7.5 mg are achieved within a short time of initiating treatment, are maintained for three months, and are not associated with any rebound in symptoms after stopping treatment. [less ▲]

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailThe OST risk tool performs consistently for identifying women at risk of osteoporosis across populations
Reginster, Jean-Yves ULg; Richy, Florent

in Annals of the Rheumatic Diseases (2004, June)

Detailed reference viewed: 31 (13 ULg)
Full Text
Peer Reviewed
See detailEtoricoxib demonstrates similar efficacy and improved gastrointestinal safety compared to naproxen in two 138-week randomized studies of osteoarthritis patients
Reginster, Jean-Yves ULg; Fischer, C. L.; Beualieu, A. et al

in Annals of the Rheumatic Diseases (2004, June)

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailClinical utility of a pharmacostatistical model for ibandronate in osteoporosis
Gieschke, R.; Reginster, Jean-Yves ULg

in Annals of the Rheumatic Diseases (2004, June)

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailA novel bisphosphonate dosing regimen: once-monthly oral ibandronate
Cooper, C.; Adami, Silvio; Stepan, J. J. et al

in Annals of the Rheumatic Diseases (2004, June)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
van de Putte, B. A.; Atkins, C.; Malaise, Michel ULg et al

in Annals of the Rheumatic Diseases (2004), 63(5), 508-516

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled ... [more ▼]

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, 40 mg weekly, or placebo. The primary efficacy end point was greater than or equal to 20% improvement in the ACR core criteria (ACR20 response). Secondary efficacy end points included ACR50, ACR70, EULAR responses, and the Disability Index of the Health Assessment Questionnaire (HAQ DI). Results: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with placebo: ACR20 (35.8%, 39.3%, 46.0%, 53.4%, respectively v 19.1%; pless than or equal to 0.01); ACR50 (18.9%, 20.5%, 22.1%, 35.0% v 8.2%; pless than or equal to 0.05); ACR70 (8.5%, 9.8%, 12.4%, 18.4% v 1.8%; pless than or equal to 0.05). Moderate EULAR response rates were significantly greater with adalimumab than with placebo (41.5%, 48.2%, 55.8%, 63.1% v 26.4%; pless than or equal to 0.05). Patients treated with adalimumab achieved better improvements in mean HAQ DI than those receiving placebo (-0.29, -0.39, -0.38, -0.49 v -0.07; pless than or equal to 0.01). No significant differences were found between adalimumab and placebo treated patients for serious adverse events, serious infections, or malignancies. Injection site reaction occurred in 10.6% and 0.9% of adalimumab and placebo treated patients, respectively (pless than or equal to 0.05). Conclusion: Among patients with RA for whom previous DMARD treatment had failed, adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated. [less ▲]

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailDegenerative musculoskeletal disease
Ethgen, Olivier ULg; Reginster, Jean-Yves ULg

in Annals of the Rheumatic Diseases (2004), 63(1), 1-3

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailOral monthly ibandronate: rationale and clinical potential in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; McClung, M.; Coutant, K. et al

in Annals of the Rheumatic Diseases (2003, June)

Detailed reference viewed: 23 (11 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
van de Putte, L. B. A.; Rau, R.; Breedveld, F. C. et al

in Annals of the Rheumatic Diseases (2003), 62(12), 1168-1177

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid ... [more ▼]

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA). METHODS: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs. RESULTS: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures. ACR20 responses with adalimumab were significant at each assessment versus placebo (p</=0.01). Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively, versus 10.0% for placebo (p</=0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%, respectively, versus 1.4% for placebo (p</=0.001 for all comparisons); and ACR70 rates were 11.3%, 10.0%, and 8.3%, respectively, versus 0.0% for placebo (p</=0.05 for all comparisons). All adalimumab doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo. CONCLUSIONS: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailRadiographic severity of knee osteoarthritis is highly correlated with future progression of the disease
Reginster, Jean-Yves ULg; Henrotin, Yves ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1), 124

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailFirst clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis
Reginster, Jean-Yves ULg; Bias, P.; Buchner, A.

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 40 (6 ULg)
Full Text
Peer Reviewed
See detailPain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs
Pavelka, K.; Rovati, Lucio C; Gatterova, J. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1), 118

Detailed reference viewed: 16 (10 ULg)
Full Text
Peer Reviewed
See detailReduction in vertebral fracture rates by a combination of monofluorophosphate and raloxifene in postmenopausal osteoporosis
Durez, P.; Felsenberg, D.; Stepan, J. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 13 (7 ULg)
Full Text
Peer Reviewed
See detailOnce weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Hosking, D.; Adami, Silvio; Felsenberg, D. et al

in Annals of the Rheumatic Diseases (2002, June), 61(Suppl.1),

Detailed reference viewed: 18 (9 ULg)
Full Text
Peer Reviewed
See detailIncreased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
Ribbens, Clio ULg; Martin y Porras, M.; Franchimont, N. et al

in Annals of the Rheumatic Diseases (2002), 61(2), 161-166

OBJECTIVE: To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) levels. METHODS: MMP-3 ... [more ▼]

OBJECTIVE: To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) levels. METHODS: MMP-3 serum levels were determined by enzyme linked immunosorbent assay (ELISA) in (a) patients with active inflammatory rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis, polymyalgia rheumatica, acute crystal arthritis, and ankylosing spondylitis; (b) patients with active inflammatory systemic diseases: cutaneo-articular or renal systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitides; (c) patients with non-inflammatory rheumatic diseases: osteoarthritis and fibromyalgia; (d) critically ill patients without rheumatic diseases, representing an acute inflammatory control group; (e) healthy controls. RESULTS: MMP-3 serum levels were significantly increased in patients with active RA, psoriatic arthritis, and polymyalgia rheumatica, whether treated or not by corticosteroids, and in female patients with acute crystal arthritis. MMP-3 serum levels were normal in steroid-free patients with active cutaneo-articular or renal SLE, systemic sclerosis, and vasculitides but were significantly increased in steroid treated patients. MMP-3 levels were normal in fibromyalgia, osteoarthritis, ankylosing spondylitis, and acute inflammatory controls. MMP-3 was significantly correlated with CRP in RA (r=0.5, p=0.0004) but not in any of the other disease groups. CONCLUSIONS: MMP-3 serum levels are increased in inflammatory rheumatic diseases characterised by joint synovitis, such as RA, polymyalgia rheumatica, psoriatic arthritis, and acute crystal arthritis-that is, whether the diseases are acute or chronic, erosive or not. They are normal in SLE, systemic sclerosis, and vasculitides as well as in non-rheumatic inflammatory controls, but are significantly increased by steroids. These data strongly suggest that serum MMP-3 reflects synovial inflammation. [less ▲]

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of classical NSAIDS and COX-2 selective inhibitors on purified ovine enzymes and human whole blood
De Leval, X; Dogne, JM; Delange, J et al

in Annals of the Rheumatic Diseases (2001), 60(S1), 343

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailLong-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads
Sanchez, Christelle ULg; Deberg, Michelle ULg; Reginster, Jean-Yves ULg et al

in Annals of the Rheumatic Diseases (2001), 60(suppl1), 284

Detailed reference viewed: 17 (6 ULg)